A gene therapy for nuclear TDP-43 supplementation: a pathway to delaying disease onset
Active Project Grant Awarded Last action
- Award ID
- HT94252510159
- Recipient
-
Macquarie University UEI CS58C37BL6W8
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $659,922
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 56% complete
- Place of performance
- Australia
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded a $659,922 Project Grant to Macquarie University in Australia under the Military Medical Research and Development program (CFDA 12.420). The grant funds a gene therapy research project aimed at developing a treatment for delaying the onset of Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The research will be conducted at Macquarie University over a 2-year period from September 2025 to September 2027. This project grant is part of the Defense Health Agency's comprehensive portfolio of basic, applied, and translational medical research initiatives focused on transforming healthcare for military personnel, veterans, and the broader public.
Quick answers
Who received award HT94252510159?
HT94252510159 was awarded to Macquarie University by Defense Health Agency (Department of Defense) on September 15, 2025.
How much is award HT94252510159 worth?
$659,922 has been obligated on HT94252510159.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award